Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/301244 
Year of Publication: 
2024
Series/Report no.: 
Research Paper No. 204
Publisher: 
South Centre, Geneva
Abstract: 
This paper analyzes the debate over the international dissemination of data exclusivity as a form of protection for clinical trial data. This is a critical demand for pharmaceutical companies seeking larger market shares and longer periods of monopoly in order to recover investments in research and development and greater profitability. However, this is a sensitive issue with economic and social repercussions for developing countries that adopt this protection regime. This paper highlights critical issues for the political economy of innovation and presents a review of empirical studies that show that data exclusivity delays the entry of generic drugs into the market, increasing prices and reducing access. At the same time, its adoption has no benefits because there are no positive effects on internal technological innovation, nor reduction of the "International drug lag", nor the development of drugs for specific epidemiological demands.
Subjects: 
Access to Medicines
Clinical Trials
Data Exclusivity
Generic Medicines
Health
Healthcare
Innovation
Intellectual Property
Pharmaceuticals
Research and Development (R&D)
Test Data
Test Data Protection
TRIPS
TRIPS Agreement
Document Type: 
Research Report
Appears in Collections:

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.